循环肿瘤DNA检测在宫颈癌诊断、治疗及预后中的应用  

Application of circulating tumor DNA detection in diagnosis, treatment and prognosis of cervical cancer

作　　者：杨海洲 左瑜芳 官成浓 YANG Hai-zhou;ZUO Yu-fang;GUAN Cheng-nong(Department of Gynecological Oncology,Guangdong Medical University Affiliated Hospital,Zhanjiang 524002,Guangdong,China;不详)

机构地区：[1]广东医科大学附属医院妇科肿瘤专科,广东湛江524002 [2]广东医科大学附属东莞第一医院肿瘤科,广东东莞523106

出　　处：《广东医学》2025年第1期150-155,共6页Guangdong Medical Journal

基　　金：广东省基础与应用基础研究基金省市联合基金项目(2023A1515140082);广东医科大学附属东莞第一医院第五批高层次人才科研资助计划资助项目(GCC2024006);广东医科大学附属东莞第一医院“攀峰100”联合培优计划资助项目(PF100-1-07)。

摘　　要：液体活检是一种操作简单的肿瘤标本获取方式,具有微创性、可重复性和易获取性等优点。临床上通过液体活检的方式可以获得相应肿瘤组织的循环肿瘤DNA(circulating tumor DNA, ctDNA)。ctDNA是直接来源于肿瘤的无细胞状态DNA,其常携带全面的肿瘤基因信息。研究发现ctDNA的检测可在肿瘤的早期诊断、靶向治疗以及预测复发中发挥作用,目前已被批准应用于多种恶性肿瘤的诊治。下文对ctDNA检测这一技术在宫颈癌的早期诊断、指导治疗、疗效评价、预测复发等方面的研究和应用进行综述,为临床工作提供参考。Liquid biopsy is an efficient method for obtaining tumor samples with advantages such as minimal invasiveness,repeatability,and ease of collection.Through liquid biopsy,circulating tumor DNA(ctDNA),a cell-free DNA directly derived from tumors,can be acquired.This DNA contains comprehensive genetic information specific to the tumor.Studies have shown that ctDNA testing can be instrumental in early cancer diagnosis,targeted therapy,and recurrence prediction.It has already been approved for use in managing various malignancies.This review provides an overview of ctDNA testing technology in cervical cancer,covering aspects such as early diagnosis,treatment guidance,therapeutic efficacy evaluation,and recurrence prediction,aiming to offer valuable insights for clinical practice.

关 键 词：宫颈癌 循环肿瘤DNA 液体活检 早期诊断 

分 类 号：R73[医药卫生—肿瘤] R737.33[医药卫生—临床医学]